Telormedix SA and Foamix Ltd., two clinical stage biopharmaceutical companies focused on TLR7 agonists in the treatment of cancer and inflammatory diseases and on topical foam delivery systems announced that they have raised funding to coordinate a two-year research project aimed at developing a new skin cancer topical treatment based on a foam formulation of one of the Company's drug candidates.
Foamix Ltd., a clinical-stage specialty pharmaceutical company, that is developing proprietary dermatological and gynecologic topical foam products, announced today that the Company has obtained another granted patent in Mexico.
Foamix Ltd., a clinical-stage specialty pharmaceutical company, that is developing proprietary dermatological and gynecologic topical foam products, today announced that the company has been granted a new patent from United States Patent Office.
Foamix, a clinical stage specialty pharmaceutical company, announced today the successful completion of the Phase II clinical trial of Minocycline foam in Impetigo patients. Minocycline Foam has shown to be highly effective against bacteria, including some multi-drug resistant strains (such as MRSA).
Foamix Ltd., a clinical-stage specialty pharmaceutical company, that is developing proprietary dermatological and gynecologic topical foam products, today announced that the company has been granted a new patent from United States Patent Office.
Foamix Ltd., a clinical-stage specialty pharmaceutical company, that is developing proprietary dermatological and gynecologic topical foam products, today announced that the company has been granted a new patent from United States Patent Office.
Foamix Ltd., a clinical-stage specialty pharmaceutical company, that is developing proprietary dermatological and gynecologic topical foam products, today announced that the company has been granted a new patent from United States Patent Office.
Most Dermatologists are concerned with Oral Minocycline side effects and will prefer prescribing their patients Topical Minocycline for Rosacea, Acne, Skin Infections and Chronic Wounds.
Herzliya, Israel and Rehovot, Israel - Arkin Holdings and Foamix today announced that they have established a collaboration to develop and commercialize an innovative topical foam to treat patients with acne vulgaris and related disorders.
The first-in-class topical Minocycline product, protected by 4 patent applications, is directed for the treatment of Rosacea, Acne, Skin Infections and Chronic Wounds.
Satisfied Users & 
Approved Press Releases
